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The size of a probe bead reported by holographic particle characterization depends on the pro-
portion of the surface area covered by bound target molecules and so can be used as an assay
for molecular binding. We validate this technique by measuring the kinetics of irreversible bind-
ing for the antibodies immunoglobulin G (IgG) and immunoglobulin M (IgM) as they attach to
micrometer-diameter colloidal beads coated with protein A. These measurements yield the anti-
bodies’ binding rates and can be inverted to obtain the concentration of antibodies in solution.
Holographic molecular binding assays therefore can be used to perform fast quantitative immunoas-
says that are complementary to conventional serological tests.
INTRODUCTION: HOLOGRAPHIC
MOLECULAR BINDING ASSAYS
Holographic molecular binding assays use holographic
particle characterization [1] to directly measure changes
in the diameters of micrometer-scale colloidal spheres
caused by molecules binding to their surfaces [2, 3]. This
rapid measurement technique eliminates the need for flu-
orescent labeling to detect binding and thus reduces the
cost, complexity, time to completion and expertise re-
quired for standard binding assays such as ELISA. Being
based on batch-synthesized beads, holographic molecular
binding assays do not require microfabricated sensors and
can be performed with comparatively little sample prepa-
ration. Holographic molecular binding assays therefore
have great promise as medical diagnostic tests, particu-
larly the serological tests required to assess patients’ im-
mune responses to pathogens such as SARS-CoV-2, the
coronavirus responsible for COVID-19.
The ability to measure nanometer-scale changes in
the diameters of micrometer-scale spheres is provided
by quantitative analysis of single-particle holograms ob-
tained with in-line holographic video microscopy [1, 4].
The hologram of an individual colloidal sphere is fit to
a generative model based on the Lorenz-Mie theory of
light scattering [5–7] to extract the particle’s diameter,
dp, refractive index, np and three-dimensional position,
~rp [1]. This measurement scheme is depicted schemati-
cally in Fig. 1. One such measurement can be completed
in a few milliseconds and yields a bead’s diameter with a
precision of 5 nm and its refractive index to within 1 ppt.
A set of such measurements can be used to measure the
mean diameter of a population of particles to within a
fraction of a nanometer [3], which is sufficient to detect
the growth of molecular-scale coatings.
Previous demonstrations of holographic molecular
binding assays [2, 3] have reported changes in probe
beads’ properties when the concentration of target
molecules is large enough to saturate the beads’ binding
sites. Here, we report concentration-dependent trends
that cover the range from zero analyte to binding-site
saturation. Interpreting these results through the statis-
tical mechanics of molecular binding then achieves three
goals: (1) to use holographic binding assays to probe
the kinetics of molecular binding; (2) to validate the
effective-sphere model used to interpret holographic par-
ticle characterization measurements on coated spheres;
and (3) to establish the effective range of analyte con-
centrations over which holographic binding assays can
quantitate target molecules in solution, a key capability
for clinical testing.
EXPERIMENTAL
We demonstrate quantitative holographic binding as-
says through measurements on antibodies binding to
beads coated with protein A, specifically immunoglob-
ulin G (IgG) and immunoglobulin M (IgM). These are
well-studied model systems [8] with which to validate
holographic binding assays and to establish their detec-
tion limits. Given the central role of IgG and IgM in the
immune response to viral pathogens, these experimen-
tal demonstrations furthermore serve as models for fast,
inexpensive and quantitative serological tests.
Probe beads and buffer solution
The probe beads used for this study (Bangs Labo-
ratories, catalog no. CP02000, lot no. 14540) have a
polystyrene core with a nominal diameter of d0 = 1µm
and a surface layer of immobilized protein A molecules,
each of which has five binding sites for the Fc region of
immunoglobulins [9, 10]. These functionalized beads are
dispersed at a concentration of 2× 106 particles/mL in an
antibody binding buffer. The same buffer is used to dis-
solve antibodies for testing. Equal volumes of the probe-
bead dispersion and the antibody solution are mixed to
initiate incubation.
The antibody binding buffer consists of 50 mM sodium
borate buffer prepared with boric acid (99.5 %, Sigma-
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2FIG. 1. (a) Schematic representation of a molecular binding assay based on holographic particle characterization. Probe beads
consist of spherical polystyrene substrates coated with functional groups (protein A) that can bind target antibodies from
solution. The probe beads have an effective diameter that increases from d0 to dp when antibodies bind. (b) A molecular-scale
coating of antibodies influences the recorded hologram of a bead. (c) This change can be quantified by fitting to predictions of
the Lorenz-Mie theory of light scattering, yielding an estimate for the fractional surface coverage and from this the concentration
of antibodies.
Aldrich, catalog no. B0394, lot no. SLBM4465V) and
NaOH (98 %, Sigma-Aldrich, catalog no. S8045, lot
no. 091M01421V) in deionized water (18.2 MΩ cm, Barn-
stead Millipure). The pH of the buffer is adjusted to 8.2
with the addition of dilute HCl (38 %, Sigma-Aldrich,
catalog no. H1758) to optimize the binding of antibodies
to protein A [11].
The dispersion of functionalized colloidal spheres con-
stitutes a bead-based assay kit for immunoglobulins that
bind to protein A. The same approach can be used to
create specific immunoassays for particular antibodies by
functionalizing the beads’ surfaces with suitable antigens
instead of protein A. Multiplexed assays can be produced
by separately functionalizing substrate beads that can be
distinguished holographically by size or by refractive in-
dex and then mixing their dispersions to make a test kit.
Assay protocol
An assay is performed by dissolving target antibodies
in the buffer at concentrations from 200 ng mL−1 up to
200 µg mL−1. Antibody solution is then mixed with an
equal volume of the stock dispersion of probe beads to
obtain a bead concentration of 106 particles/mL and an-
tibody concentrations in the range from 100 ng mL−1 to
100 µg mL−1. This easily allows for detection in a phys-
iologically relevant range following suitable dilution, as
the typical concentration of immunoglobulins in human
serum is 10 mg mL−1 [12]. The sample is allowed to equi-
librate for τ = 45 min at room temperature before being
analyzed.
To model immunoassays that would be relevant for
serological testing, we performed assays on rabbit IgG
(EMD Millipore; catalog no. PP64, lot no. 3053798)
and human IgM (Sigma-Aldrich; catalog no. I8260, lot
no. 069M4838V). Aggregation of IgM is suppressed by
increasing the ionic strength of the buffer through the
addition of 150 mM of NaCl (99.5 %, Sigma-Aldrich, cat-
alog no. S7653) [13].
Control measurements are performed by replacing the
antibodies with alcohol dehydrogenase (ADH, Sigma-
Aldrich; catalog no. A3263-7.5KU, lot no. SLBW31382).
Non-specific binding due to incomplete coverage of the
bead surfaces by protein A is blocked for these experi-
ments by incubating the probe beads with bovine serum
albumin (BSA, Sigma-Aldrich, catalog no. A2153). BSA
adsorbs non-specifically to exposed polystyrene and does
not interfere with antibody binding to protein A. ADH
does not bind to either protein A or BSA and thus should
not attach to the probe beads. With a molecular weight
greater than 140 kDa, ADH is comparable in size to IgG
and thus should have a similar holographic signature,
were it to bind.
Holographic particle characterization
Holographic particle characterization measurements
are performed with a commercial holographic parti-
cle characterization instrument (Spheryx xSight) set to
record holograms at a wavelength of 447 nm. Each mea-
surement involves pipetting a 30 µL aliquot of the disper-
sion into the sample reservoir of one channel in an eight-
channel microfluidic chip (Spheryx xCell). The sample
chip is then loaded into xSight, which is set to draw
1 µL of the sample through the observation volume in a
pressure-driven flow with a peak speed around 3 mm s−1.
Data for a thousand beads is collected in measurement
time ∆τ = 2 min and is fully analyzed in about 15 min.
The Lorenz-Mie theory used to analyze holograms
treats each particle as a homogeneous sphere. When
applied to inhomogeneous particles, such as the coated
spheres in the present study, the extracted parameters
must be interpreted as representing the properties of an
effective sphere [14–16]. These effective-sphere proper-
3ties will differ from the physical properties of the coated
sphere unless the coating has the same refractive index as
the substrate bead. The refractive index of the coating,
moreover, depends on the fraction, f , of binding sites
occupied by molecules, which means that the effective
diameter of the coated sphere also depends on f . Nu-
merical studies show that the holographically measured
diameter increases linearly with surface coverage [16],
dp = d0 + 2δ f, (1)
where d0 is the bare sphere’s diameter and δ is the ef-
fective optical thickness of a complete layer of bound
molecules. The value of δ depends on the size of the
target molecule, the density of binding sites, and the re-
fractive index of the target molecule relative to those of
the medium and the substrate bead [16].
Each dispersed particle is recorded and analyzed up
to 10 times as it traverses the observation volume and
the resulting three-dimensional position measurements
are linked into a trajectory [17]. The linked measure-
ments are combined to improve the precision of the es-
timated values for the particle’s diameter and refractive
index [2]. Typical results for a sample of beads incubated
with 10µg mL−1 of IgG are presented in Fig. 2. Each
point in these scatter plots represents the holographically
measured trajectory, Fig. 2(a), and properties, Fig. 2(b),
of a single particle. The size of the dots is comparable to
the estimated measurement precision.
Single particle trajectories are useful for mapping the
fluid flow in the microfluidic channel. [2] Figure 2(a)
shows the beads’ speed, vp(zp), as a function of axial po-
sition, zp, relative to the instrument’s focal plane. Data
points in Fig. 2(a) are colored by the spheres’ measured
diameters and show that particles are distributed uni-
formly throughout the channel and that particle size is
not correlated with height in the channel. Fitting these
data to the anticipated parabolic Poiseuille flow profile
yields estimates for the positions of the upper and lower
walls of the channel, which are indicated by the horizon-
tal dashed lines in Fig. 2(a). Mapping the flow profile
provides an important internal reliability check, ensuring
that the sample has flowed smoothly through the chan-
nel, that the microfluidic channel is properly seated in
the instrument, and that trajectory linking has proceeded
correctly.
Figure 2(b) show the single-particle characterization
data obtained from these trajectories, with each point
representing the effective diameter, dp, and refractive in-
dex, np, of a single bead. Plot symbols are colored by
the density of observations, ρ(dp, np).
The 890 particles in this data set enable us
to compute the population-average diameter, dp =
(0.974± 0.002) µm and the mean refractive index, np =
1.5692± 0.0008. The value for the refractive index is
significantly smaller than the value of 1.60 expected
for polystyrene at the imaging wavelength, and is con-
sistent with expectations for a coated sphere in the
effective-sphere interpretation [16]. The mean diam-
eter is significantly larger than the baseline value of
d0 = (0.964± 0.002) µm obtained for the probe beads
alone. The difference, ∆p = dp − d0 = (10± 3) nm is
consistent with a statistically significant detection of an-
tibody binding [3] at concentrations orders of magnitude
lower than physiological levels [12, 18, 19].
A principal aim of the present study is to combine
the effective-sphere analysis of probe beads’ holograms
[2, 3, 16] with the statistical physics of molecular binding
to obtain quantitative information on the kinetics of anti-
body binding from measurements of dp(c, t). Conversely,
this analysis establishes that a holographically observed
shift in bead diameter can be used to measure the concen-
tration of antibodies in solution and furthermore estab-
lishes the trade-off between concentration sensitivity and
measurement time for such holographic immunoassays.
Kinetics of molecular binding
Antibodies bind rapidly to protein A in the antibody
binding buffer and the rate of dissociation is small enough
for the process to be considered irreversible [20]. Anti-
bodies therefore continue to bind to the probe beads un-
til all of the surface sites are saturated or the solution
is depleted. Assuming that depletion may be ignored
and the solution remains well mixed, the fraction of oc-
cupied sites, f(c, t), increases at a rate that depends on
the concentration of antibodies, c, and the availability of
unoccupied sites [21–23]
df
dt
= γ(c)[1− f(c, t)]. (2)
This model differs from those in previous studies [24–26]
by not having to account for detachment of antibodies
from binding sites. Minimizing unbinding optimizes the
sensitivity of the assay to small concentrations of analyte
and reduces the time required to perform measurements.
The rate constant, γ(c), accounts for the microscopic
kinetics of molecular binding. Further assuming that the
concentration of antibodies is low enough that binding
events are independent, we model γ(c) = kc, where k
is the binding rate for the antibodies in the antibody
binding buffer. The solution to Eq. (2),
f(c, t) = 1− e−kct, (3)
satisfies the initial condition f(c, 0) = 0 and shows that
binding assays can be performed either as a function of
time for fixed antibody concentration, c, or as a function
of concentration at fixed incubation time, t. If, further-
more, the measurement is performed over a time interval,
4FIG. 2. Typical holographic molecular binding assay for a sample of probe beads incubated with 10µg mL−1 IgG. (a) Holo-
graphically measured velocity profile. Each point represents the speed, vp, of a single bead as a function of its axial position,
zp, relative to the instrument’s focal plane. The solid curve is a fit to the parabolic Poiseuille flow profile. Horizontal dashed
lines indicate the axial positions of the channel’s walls inferred from this fit. Points are colored by each particle’s measured
diameter, dp. Evenly mixed colors demonstrate that the results are not biased by the particles’ positions in the channel. (b)
Holographic characterization data for the same sample of beads showing the distribution of single-particle diameter, dp, and
refractive index, np. Points are colored by the density of measurements, ρ(dp, np). The central point shows the population
mean for this sample and is sized to represent the uncertainty in the mean.
∆τ , starting after incubation time τ , the average cover-
age is
f¯(c, τ) =
1
∆τ
∫ τ+∆τ
τ
f(c, t) dt (4a)
= 1− 1− e
−kc∆τ
kc∆τ
e−kcτ . (4b)
Monitoring binding holographically
Combining Eq. (1) with Eq. (4) yields an expression
for the dependence of the measured bead diameter on
the target molecules’ concentration in solution:
∆d(c, τ) ≡ dp − d0 = 2δ
(
1− 1− e
−kc∆τ
kc∆τ
e−kcτ
)
. (5)
Holographic measurements of ∆d(c, τ) at fixed incuba-
tion time τ can be interpreted with Eq. (5) to estimate
the effective layer thickness, δ, and the rate constant,
k. These values, in turn, can be used to anticipate how
the sensitivity of the assay for antibody concentration
depends on incubation time, τ . This sensitivity can be
further improved by reducing uncertainties in ∆d(c, τ),
either by extending the measurement time to analyze
more beads or by optimizing the optical properties of
the beads to increase δ [16].
RESULTS
The discrete points in Fig. 3 show measured shifts,
∆d(c, τ), in the population-average bead diameter after
τ = 45 min incubation with (a) IgG, (b) IgM and (c)
ADH. These shifts are measured in nanometers and illus-
trate the precision with which holographic particle char-
acterization can resolve the diameters of probe beads.
Error bars indicate uncertainties in the mean diameter
given the particle-counting statistics for each measure-
ment. A single point represents results from roughly 1000
beads observed in 1 µL of the sample over ∆τ = 2 min.
As anticipated, bead diameters increase upon incuba-
tion with antibodies by an amount that depends on an-
tibody concentration. Incubation with ADH has no such
effect presumably because ADH does not bind to protein
A. Results for IgG and ADH are presented for concen-
trations up to 100µg mL−1. IgM is plotted only up to
20 µg mL−1 because ∆d(c, t) reaches a plateau beyond
c = 5µg mL−1, which we interpret to represent satura-
tion of the available surface sites by IgM.
The solid curves in Fig. 3(a) and Fig. 3(b) are fits of
the measured bead diameters to Eq. (5) for the appar-
ent layer thickness, δ, and the rate constant, k. Interest-
ingly, fits to the data for both IgG and IgM are consistent
with an effective layer thickness of δ = (8.0± 0.5) nm
even though IgM has five times the molecular weight of
IgG. This agreement could be a coincidence arising from
the effective-sphere interpretation of holographic imag-
ing data [16]. It also is consistent with a model in which
multi-site binding of the predominantly pentameric IgM
5FIG. 3. Holographic molecular binding assays for (a) IgG (red circles) and (b) IgM (green squares) to colloidal beads coated
with protein A dispersed in antibody binding buffer. IgM assay is performed with 150 mM added NaCl to suppress aggregation.
Discrete points show the increase, ∆d(c, τ) = dp(c, τ)−d0, of the population-average effective-sphere diameter, dp(c, τ), relative
to the probe beads’ reference diameter, d0, as a function of antibody concentration, c after fixed incubation time τ = 45 min.
Solid curves are best-fits to Eq. (5) for measurement time ∆τ = 2 min. (c) 45 minute incubation with alcohol dehydrogenase
(ADH) has no measurable affect on probe bead diameters. (d) Binding data collapsed according to Eq. (5). Concentrations
are scaled by kτ and diameter shifts are scaled by the layer thickness, δ.
assembly results in a flattened orientation of the IgM on
the probe beads’ surfaces, thus contributing no more to
δ than the single domain of IgG.
The fit value for the rate constant of IgG is
kG = (1.2± 0.3)× 10−5 mL µg−1 s−1, which corre-
sponds to a rate per binding site of mGkG =
(3.0± 0.8)× 10−18 mL s−1, given the mG = 150 kDa
molecular weight of IgG. We express this figure as a rate
of binding events per surface site rather than as a rate
per molecule to emphasize that the molecules are filling
available binding sites on the probe beads.
The corresponding rate constant for IgM, kM =
(2.5± 0.8)× 10−4 mL µg−1 s−1, is an order of mag-
nitude greater than kG. The difference becomes
even greater when account is taken of the mM =
970 kDa molecular mass of pentameric IgM: mMkM =
(4.1± 1.2)× 10−16 mL s−1. Naively assuming that each
IgG molecules occupies νG = 1 binding site and each IgM
occupies νM = 5 reduces the difference proportionately,
mMkM
νM
νG
mGkG
= 27± 1. (6)
The remaining large difference in binding rates cannot be
ascribed to differences in bulk transport properties be-
cause the molecules’ diffusion constants are proportional
to their sizes, which suggests that IgG should attach more
rapidly, being smaller. It may instead reflect differences
in the two antibodies’ microscopic binding mechanisms
[27]. Possible explanations include differences in binding
probabilities as molecules approach the surface due to
the multivalent presentation of binding sites for the pen-
tameric IgM. In addition, different barriers to attachment
may arise due to variations in the nature of electrostatic
interactions for immunoglobulins. A more thorough eval-
uation of the influence of multivalency on attachment ki-
netics for IgGs, IgMs and other biomacromolecules will
6provide an intriguing challenge for our future studies.
Nevertheless, even a simplified model such as a one-to-
one binding mode between Protein A and IgG, for exam-
ple, provides the capability to conduct chemical analysis
of immunoglobulin concentration in solution.
Given our primary goal of developing immunoassays
for serological testing, the experimental results in Fig. 3
confirm that holographic particle characterization pro-
vides a basis for quantitative measurements of antibody
concentrations under physiological conditions. The suc-
cess of these fits to a kinetic model for attachment is
demonstrated by the data collapse in Fig. 3(d), with re-
sults from IgG and IgM both falling on the same master
curve despite the substantial difference in the two anti-
bodies’ rate constants.
CONCLUSION
This study has demonstrated that holographic parti-
cle characterization can perform quantitative molecular
binding assays, including measuring the rate constants
that characterize molecular binding. Our results demon-
strate that a single 15 min measurement can quantify the
concentration of IgG in solution down to concentrations
as low as 10µg mL−1 and concentrations of IgM as low as
1 µg mL−1. Longer measurements and larger statistical
samples can improve this sensitivity, both by increasing
occupancy of binding sites and also by reducing uncer-
tainty in the diameter shift.
Whereas the IgG-protein A system has been studied
extensively, less has been written about binding of IgM
to substrates coated with protein A. The holographic as-
says reported here provide insights into the binding mech-
anism that may inform future studies. We find, for exam-
ple, that IgM tends to bind significantly more rapidly to
protein A than IgG. Our observations also suggest that
IgM may tend to bind flat to the surface of a functional-
ized bead. How these trends depend on such factors as
electrolyte composition and concentration fall outside the
intended scope of the present study and will be addressed
elsewhere.
Using protein A to provide binding functionalization
yields a general-purpose assay for antibody concentra-
tion, rather than an immunoassay for specific antibodies.
This general-purpose assay already should be useful as
a rapid screening test for Antibody Deficiency Disorders
[28, 29].
Holographic immunassays can be targeted for specific
diseases by replacing protein A as a surface binding group
with appropriate specific antigens, including peptides,
proteins, or other biomolecules. Such functionalized col-
loidal spheres are standard components of conventional
bead-based assays, which typically rely on fluorescent
labels for readout. Holographic analysis yields results
faster and at lower cost by eliminating reagents, process-
ing steps and expertise needed to apply fluorescent labels.
Holographic analysis furthermore yields quantitative re-
sults for antibody concentration without requiring exten-
sive calibration. The speed and sensitivity of holographic
immunoassays can be improved further by optimizing the
sizes and optical properties of the substrate beads. Such
efforts currently are under way.
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